J&J cuts number of participants in its vaccine trial from 60,000 to 40,000

Johnson and Johnson say interim vaccine data may be available by the end of January if the vaccine is safe and effective and an emergency use authorization could be submitted in February. Meg Tirrell joins 'Closing Bell' to discuss.